A new study uses advanced imaging and spatial analysis to predict how patients with Non-Small Cell Lung Cancer (NSCLC) respond to the combination of Pembrolizumab and Vorinostat. Unlike standard PD-L1 testing, this approach maps the tumor microenvironment at the single-cell level and analyzes spatial patterns of immune and tumor cells.
Researchers identified two distinct tumor “ecologies”: patients with Stable Disease (SD) had high infiltration of CD8+ T cells and other immune cells (“hot” tumors), while patients with Progressive Disease (PD) had more regulatory T cells (FoxP3+) at tumor borders (“cold” tumors). These patterns were quantified using a new metric called RoGM (Ratio of Geometric Means), which predicts treatment response: high RoGM indicates a favorable immune environment, low RoGM indicates likely resistance.
By viewing tumors as dynamic ecosystems, this spatial omics method can better predict which patients will respond to immunotherapy, potentially improving treatment decisions beyond traditional biomarkers.